Clinicopathologic features and management of blastoid variant of mantle cell lymphoma

Rajesh Shrestha, Vijaya R Bhatt, Guru Subramanian Guru Murthy, James Olen Armitage

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

The blastoid variant of mantle cell lymphoma (MCL), which accounts for less than one-third of MCL, may arise de novo or as a transformation from the classical form of MCL. Blastoid variant, which predominantly involves men in their sixth decade, has frequent extranodal involvement (40-60%), stage IV disease (up to 85%) and central nervous system (CNS) involvement. Diagnosis relies on morphological features and is challenging. Immunophenotyping may display CD23 and CD10 positivity and CD5 negativity in a subset. Genetic analysis demonstrates an increased number of complex genetic alterations. Blastoid variant responds poorly to conventional chemotherapy and has a short duration of response. Although the optimal therapy remains to be established, CNS prophylaxis and the use of aggressive immunochemotherapy followed by autologous stem cell transplant may prolong the remission rate and survival. Further studies are crucial to expand our understanding of this disease entity and improve the clinical outcome.

Original languageEnglish (US)
Pages (from-to)2759-2767
Number of pages9
JournalLeukemia and Lymphoma
Volume56
Issue number10
DOIs
Publication statusPublished - Oct 3 2015

    Fingerprint

Keywords

  • Mantle cell lymphoma
  • autologous stem cell transplant
  • blastoid variant
  • central nervous system involvement
  • genetic alteration
  • high dose chemotherapy
  • intensified chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this